FDA approves Leo Pharma's tralokinumab after rejection 8 months ago

Eight months after Leo Pharma's atopic eczema treatment, tralokinumab, was rejected in the US, the FDA gives the Danish firm's drug the thumbs-up. Leo Pharma can now market and sell the drug in the US, which could double the company's size, says Leo Pharma executive Becki Morison.

Leo Pharma is turning a page with the FDA's historic approval of tralokinumab as a treatment of atopic eczema, says a Leo Pharma executive | Photo: Leo Pharma / PR

The US Food and Drug Administration (FDA) approves of Leo Pharma's biologic drug, tralokinumab, against atopic eczema in adults, Leo Pharma announce in a press release.

The FDA had rejected Leo Pharma's first application back in April, requesting more data on a device component related to the pre-filled syringe used to administer the drug.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs